LabLogic radiochromatography systems assist cancer antibody trials

LabLogic radiochromatography systems assist cancer antibody trials
The School of Medicine at the UK's Southampton University is using radio HPLC and radio TLC systems from LabLogic in connection with clinical trials for treating haematological malignancies.
 
FOR IMMEDIATE RELEASE

PRLog (Press Release) - Nov 30, 2010 - The Cancer Sciences Division of Southampton University School of Medicine is using radio HPLC and radio TLC systems from LabLogic in the development and quality control of radio-labelled antibody conjugates undergoing clinical trials for treating haematological malignancies.

The HPLC system incorporates an Agilent quaternary pump, an auto-degasser and a thermostatically controlled column compartment.

"We have had the equipment for ten months now, and it has proved to be a sensitive and reliable upgrade from our previous system," says John Langford, head of the laboratory.

"It is always easy to use, whether we are measuring the gamma emissions of indium-111 or the beta emissions of yttrium-90.  And the speed and ease of use of LabLogic's Laura radiochromatography software means that results are available immediately after the end of each run.

"We often correlate our results to ITLC for confirmation, and here we're finding that the LabLogic radio-TLC scanner provides more detail than the ‘cut and count' method.  It makes it easier to locate peaks and discriminate between them and it uses the same Laura software, which is very convenient."

# # #


LabLogic Systems has been supplying nucleonic instrumentation and scientific software since 1979. Principal clients are pharmaceutical, agrochemical and contract research organisations, who use the company's products in their research and development activities.

--- end ---

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.